Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
Cancer Letters
|
December 3, 2014
miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma
Tae Hoen Kim, Ji-Ye Song, Hyun Park, et al.
Cancer Letters
|
November 27, 2016
MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3
Ju-Yeon Jeong, Haeyoun Kang, Tae Hoen Kim, et al.
International Journal of Molecular Sciences
|
November 9, 2024
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer
Sa Deok Hong, Nar Bahadur Katuwal, Min Sil Kang, et al.
Cancers
|
October 14, 2023
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
Yeong Gyu Jeong, Nar Bahadur Katuwal, Min Sil Kang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
November 29, 2023
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Nar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
June 15, 2018
A clinicopathologic review and obstetric outcome of uterine smooth muscle tumor of uncertain malignant potential (STUMP) in a single institution
Hyeong In Ha, Min Chul Choi, Jin Hyung Heo, et al.
Cancer Research
|
September 4, 2016
Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1
Jin-Gyoung Jung, Ie-Ming Shih, Joon Tae Park, et al.
Journal of Cancer
|
June 18, 2019
Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas
Sewha Kim, Min Chul Choi, Ju-Yeon Jeong, et al.
British Journal of Cancer
|
May 6, 2026
JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models
Min Sil Kang, Nar Bahadur Katuwal, Mithun Ghosh, et al.
Cancers
|
August 27, 2021
<i>USP19</i> and <i>RPL23</i> as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma
Haeyoun Kang, Min Chul Choi, Sewha Kim, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
Cancer Letters
|
December 3, 2014
miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma
Tae Hoen Kim, Ji-Ye Song, Hyun Park, et al.
Cancer Letters
|
November 27, 2016
MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3
Ju-Yeon Jeong, Haeyoun Kang, Tae Hoen Kim, et al.
International Journal of Molecular Sciences
|
November 9, 2024
Trastuzumab-Mediated Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Enhances Natural Killer Cell Cytotoxicity in HER2-Overexpressing Ovarian Cancer
Sa Deok Hong, Nar Bahadur Katuwal, Min Sil Kang, et al.
Cancers
|
October 14, 2023
Combined PI3K Inhibitor and Eribulin Enhances Anti-Tumor Activity in Preclinical Models of Paclitaxel-Resistant, PIK3CA-Mutated Endometrial Cancer
Yeong Gyu Jeong, Nar Bahadur Katuwal, Min Sil Kang, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
November 29, 2023
Targeting PEG10 as a novel therapeutic approach to overcome CDK4/6 inhibitor resistance in breast cancer
Nar Bahadur Katuwal, Min Sil Kang, Mithun Ghosh, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|
June 15, 2018
A clinicopathologic review and obstetric outcome of uterine smooth muscle tumor of uncertain malignant potential (STUMP) in a single institution
Hyeong In Ha, Min Chul Choi, Jin Hyung Heo, et al.
Cancer Research
|
September 4, 2016
Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1
Jin-Gyoung Jung, Ie-Ming Shih, Joon Tae Park, et al.
Journal of Cancer
|
June 18, 2019
Serum exosomal miRNA-145 and miRNA-200c as promising biomarkers for preoperative diagnosis of ovarian carcinomas
Sewha Kim, Min Chul Choi, Ju-Yeon Jeong, et al.
British Journal of Cancer
|
May 6, 2026
JPI-547, a novel dual inhibitor of PARP1/2 and tankyrase is more effective than first-generation PARP inhibitors in preclinical BRCA1/2-mutated cancer models
Min Sil Kang, Nar Bahadur Katuwal, Mithun Ghosh, et al.
Cancers
|
August 27, 2021
<i>USP19</i> and <i>RPL23</i> as Candidate Prognostic Markers for Advanced-Stage High-Grade Serous Ovarian Carcinoma
Haeyoun Kang, Min Chul Choi, Sewha Kim, et al.
Page
of 3